➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Medtronic
McKinsey
Moodys

Last Updated: February 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ABILIFY MYCITE KIT

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for ABILIFY MYCITE KIT

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03643159 A Trial to Measure the Difference in All-cause Hospitalizations for Patients Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder Terminated Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 4 2018-06-29 A pragmatic clinical trial (Main Study) to assess the difference between all-cause hospitalizations in patients using Abilify MyCite versus virtual matched controls. Eligible patients will enter a screening period of up to 13 days. At enrollment, patients will receive treatment with Abilify MyCite for 3 months and discontinue the use of Abilify MyCite during the following 3 months (and the patient continues with oral aripiprazole or other appropriate treatment). Thereafter, the patient has the option to start and stop Abilify MyCite (up to 6 months of Abilify MyCite) per the joint decision of the patients with their study physician. A parallel exploratory study will utilize a different set of physicians and patients from the main study. Procedures for the exploratory study will be similar to those in the Main Study, with the exception that there will be 1-month intervals of Abilify MyCite use (and 1-month intervals of prohibition of Abilify MyCite use).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ABILIFY MYCITE KIT

Condition Name

Condition Name for ABILIFY MYCITE KIT
Intervention Trials
Schizophrenia 1
Major Depressive Disorder 1
Bipolar I Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ABILIFY MYCITE KIT
Intervention Trials
Depressive Disorder 1
Depression 1
Schizophrenia 1
Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ABILIFY MYCITE KIT

Trials by Country

Trials by Country for ABILIFY MYCITE KIT
Location Trials
United States 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ABILIFY MYCITE KIT
Location Trials
Ohio 1
Nevada 1
Georgia 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ABILIFY MYCITE KIT

Clinical Trial Phase

Clinical Trial Phase for ABILIFY MYCITE KIT
Clinical Trial Phase Trials
Phase 4 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ABILIFY MYCITE KIT
Clinical Trial Phase Trials
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ABILIFY MYCITE KIT

Sponsor Name

Sponsor Name for ABILIFY MYCITE KIT
Sponsor Trials
Otsuka Pharmaceutical Development & Commercialization, Inc. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ABILIFY MYCITE KIT
Sponsor Trials
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
Baxter
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.